Document is current
Any future updates will be listed below
-
Authors
Larrieu, Thomas https://orcid.org/0000-0003-2406-356X
Grieco, Fabio
Carron, Charline
Vilademunt, Marta
Weber, Crystal
Ginggen, Kyllian
Delacrétaz, Aurélie
Gallart-Ayala, Hector https://orcid.org/0000-0003-2333-0646
Tsuda, Mumeko C.
Cameron, Heather A. https://orcid.org/0000-0002-3245-5777
Eap, Chin B.
Ivanisevic, Julijana https://orcid.org/0000-0001-8267-2705
Magistretti, Pierre
Salta, Evgenia
Tosoni, Giorgia https://orcid.org/0000-0003-0787-8556
Ayyildiz, Dilara
Telley, Ludovic https://orcid.org/0000-0002-5041-1997
Dayer, Alexandre
Piguet, Camille
Toni, Nicolas https://orcid.org/0000-0001-5585-268X
-
Funding
Funding for this research was provided by:
Swiss National Science Foundation | National Center of Competence in Research Affective Sciences - Emotions in Individual Behaviour and Social Processes (31003A_173128)
- License Information
-
More Information
Article History
Received: 20 January 2025
Accepted: 27 January 2026
First Online: 6 February 2026
Competing interests
: N.T. and T.L. have filed a patent application. Patent applicant: Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland (institutional applicant). Inventors: N.T. and T.L. Application number: PCT/EP2025/064764. Status of application: International patent application pending (PCT). Specific aspect of the manuscript covered by the patent application: Therapeutic methods targeting LPA16:0–LPAR1/LPAR3 signaling for the treatment and/or prevention of neuropsychiatric and emotional dysregulation disorders, particularly anxiety-related phenotypes. Diagnostic methods and kits for measuring circulating LPA16:0 levels in biological samples to stratify subjects (e.g., high- vs low-anxiety, stress susceptibility/resilience). Use of LPA16:0 as a biomarker linked to hippocampal neurogenesis and stress resilience, including pharmacological modulation of LPAR1/3 activity.
